GlassScriptPhysician profile
Leia Michele Hunt
NPI 1366781460
$3,230.96
in general payments reported to CMS, 2019-2025
25 companies · $963 in 2025
The $963 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $96.43 · 2022: $555 · 2023: $506 · 2024: $1,111 · 2025: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,508 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,508.01 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $516.30 | 2022-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $381.45 | 2024-2025 | Zoryve |
| Genzyme Corporation | $364.73 | 2022-2025 | |
| Abbvie INC. | $309.99 | 2021-2025 | |
| Galderma Laboratories, L.P. | $296.26 | 2023-2025 | Nemluvio, Aklief |
| Incyte Corporation | $282.81 | 2022-2025 | Opzelura, Opzelura |
| Organogenesis INC. | $270.00 | 2023-2024 | Puraply |
| Leo Pharma INC. | $203.10 | 2023-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $107.71 | 2025 | |
| Mayne Pharma Commercial LLC | $76.58 | 2025 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $38.35 | 2022-2024 | Cabtreo |
| Paratek Pharmaceuticals, INC. | $33.79 | 2024 | Nuzyra |
| Lilly USA, LLC | $31.66 | 2021-2022 | |
| Ucb, INC. | $31.27 | 2025 | Bimzelx |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $30.54 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $24.43 | 2025 | |
| Almirall LLC | $24.25 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $23.28 | 2024 | Sotyktu |
| Organon LLC | $21.99 | 2025 | |
| Verrica Pharmaceuticals INC. | $20.21 | 2024 | Ycanth |
| Mallinckrodt Hospital Products INC. | $19.20 | 2025 | Acthar |
| Epi Health, LLC | $17.86 | 2022 | |
| Biofrontera INC. | $17.03 | 2021 | |
| Dermavant Sciences, INC. | $16.17 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leia Hunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.